Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gail T Colbern

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Lab Animal|September 21, 2012
Response to protocol review scenario: first do no harmGail T Colbern
Lab Animal|October 25, 2007
Should clinical complications affect USDA pain categories? C is correctGail T Colbern, Lisa Heath
Seminars in Oncology|February 19, 2005
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studiesDavid M Vail, Michael A Amantea, Gail T Colbern, et al.
Frontiers in Bioscience (Elite Edition)|December 29, 2009
Characterization of a novel, trastuzumab resistant human breast cancer cell lineMark Barok, Margit Balazs, Viktoria Lazar, et al.
Cancer Chemotherapy and Pharmacology|August 13, 2002
STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trialDavid M Vail, Ilene D Kurzman, Phyllis C Glawe, et al.
Seminars in Oncology|February 19, 2005
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancerNicholas J Robert, Charles L Vogel, I Craig Henderson, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Lab Animal|September 21, 2012
Response to protocol review scenario: first do no harmGail T Colbern
Lab Animal|October 25, 2007
Should clinical complications affect USDA pain categories? C is correctGail T Colbern, Lisa Heath
Seminars in Oncology|February 19, 2005
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studiesDavid M Vail, Michael A Amantea, Gail T Colbern, et al.
Frontiers in Bioscience (Elite Edition)|December 29, 2009
Characterization of a novel, trastuzumab resistant human breast cancer cell lineMark Barok, Margit Balazs, Viktoria Lazar, et al.
Cancer Chemotherapy and Pharmacology|August 13, 2002
STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trialDavid M Vail, Ilene D Kurzman, Phyllis C Glawe, et al.
Seminars in Oncology|February 19, 2005
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancerNicholas J Robert, Charles L Vogel, I Craig Henderson, et al.
Pageof 1